SCHEMBL320396

SCHEMBL320396

CCCn1c(=O)[nH]c2ccc(C(=O)c3c(C)c(-c4cccc(C(=O)O)c4)c4ccccn34)cc2c1=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.43
HPGD P15428 4/20 0.43
GAA P10253 3/20 0.43
HSD17B10 Q99714 3/20 0.43
KDM4E B2RXH2 2/20 0.43
ADORA3 P0DMS8 2/20 0.39
ADORA2B P29275 2/20 0.39
ADORA1 P30542 1/20 0.39
PPARG P37231 1/20 0.38
NPC1 O15118 1/20 0.38
MAPT P10636 3/20 0.37
TP53 P04637 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.36
MAPK8 P45983 1/20 0.36
HTT P42858 2/20 0.36
CNR2 P34972 1/20 0.36
RAB9A P51151 1/20 0.36
B3GNT2 Q9NY97 1/20 0.36
TUBB4A P04350 1/20 0.35
TUBB P07437 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL321765 0.82 RORC (0.43) ALDH1A1HPGDGAAHSD17B10KDM4E
SCHEMBL14917190 0.82 NPC1 (0.40) ALDH1A1HPGDGAAHSD17B10KDM4E
SCHEMBL15067756 0.79 MCL1 (0.35) ALDH1A1GAAHSD17B10KDM4EPPARG
SCHEMBL320892 0.78 ALDH1A1 (0.41) ALDH1A1HPGDGAAHSD17B10KDM4E
SCHEMBL320647 0.77 ALDH1A1 (0.41) ALDH1A1HPGDGAAHSD17B10KDM4E
SCHEMBL321532 0.76 NPC1 (0.44) ALDH1A1HPGDGAAHSD17B10KDM4E
SCHEMBL15067912 0.76 MEN1 (0.36) ALDH1A1HPGDHSD17B10KDM4EADORA3
SCHEMBL15067731 0.75 MAPT (0.35) ALDH1A1GAAHSD17B10KDM4EPPARG
SCHEMBL15067410 0.75 MAPT (0.35) ALDH1A1GAAHSD17B10KDM4EPPARG
SCHEMBL15068073 0.75 MEN1 (0.36) ALDH1A1HPGDGAAHSD17B10KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2590975-B1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2015-08-19 EP disclosed
US-8859544-B2 Indolizine derivatives, process for the preparation thereof and therapeutic use thereof SANOFI (FR) 2014-10-14 US disclosed
EP-2590975-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-05-15 EP disclosed
US-20130116249-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-05-09 US disclosed
WO-2012004731-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2012-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116249-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CCNY, INMT, IDO1 ALDH1A1 3536/4885HPGD 810/4885GAA 3839/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.